证券代码：600833 证券简称：第一医药 公告编号：临 2024-032 上海第一医药股份有限公司 第十届董事会第二十四次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十届董事会第二十四次（临时） 会议于 2024 年 5 月 31 日以邮件方式通知，于 2024 年 6 月 5 日以通讯方式召开。本次 会议由董事长张海波先生召集并主持。本次会议应参加表决董事为 9 名，委托表决 0 名， 实际参加表决董事 9 名。会议的召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《关于补选第十届董事会独立董事的议案》 补选陈少雄先生为公司第十届董事会独立董事，任期自股东大会审议通过之日起至 公司第十届董事会届满之日止。公司董事会提名委员会发表了同意的事前审阅意见，该 项议案尚需提交公司 2024 年 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2024-033 上海第一医药股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2024 年 6 月 21 日 9 点 30 分 召开地点：上海市徐汇区 681 号上海外经大厦 20 楼第三会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 股东大会召开日期：2024年6月21日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票起止时间：自 2024 年 6 月 21 日 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第二次临时股东大会 至 2024 年 6 月 21 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 462,073,365.11, representing a year-on-year increase of 0.65%[5]. - The net profit attributable to shareholders for the same period was CNY 36,053,836.02, reflecting a significant increase of 21.75% compared to the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 43.55%, amounting to CNY 4,445,109.23, primarily due to reduced sales of related materials[5][8]. - The basic earnings per share for Q1 2024 were CNY 0.1616, up by 21.79% year-on-year[5]. - The weighted average return on net assets was 3.51%, an increase of 0.47 percentage points compared to the previous year[5]. - Total profit for Q1 2024 was CNY 47,904,890.21, an increase of 23.3% compared to CNY 38,846,843.85 in Q1 2023[18]. - The net profit for Q1 2024 was CNY 36,053,836.02, an increase of 21.8% compared to CNY 29,612,934.80 in Q1 2023[19]. - Basic and diluted earnings per share for Q1 2024 were CNY 0.1616, up from CNY 0.1327 in Q1 2023, reflecting a growth of 21.5%[19]. Cash Flow and Liquidity - The net cash flow from operating activities saw a drastic decline of 90.65%, totaling CNY 10,368,722.94, mainly due to the timing of sales refunds[5][8]. - Cash flow from operating activities generated a net amount of CNY 10,368,722.94, a significant decrease of 90.7% from CNY 110,910,482.82 in the same period last year[23]. - The company’s operating cash inflow decreased by 13.4% from CNY 605,721,343.28 in Q1 2023 to CNY 524,458,564.26 in Q1 2024[23]. - Total cash inflow from investment activities was CNY 90,261,106.91, while cash outflow was CNY 113,582,191.78, resulting in a net cash outflow of CNY 23,321,084.87[24]. - Cash flow from financing activities yielded a net inflow of CNY 4,362,688.95, compared to a net outflow of CNY 15,052,939.22 in Q1 2023[24]. - The company reported cash and cash equivalents at the end of Q1 2024 amounting to CNY 390,586,970.52, slightly up from CNY 387,989,848.26 at the end of Q1 2023[24]. - Cash and cash equivalents as of March 31, 2024, were CNY 392,085,876.61, a decrease from CNY 400,027,992.47 as of December 31, 2023[12]. Assets and Liabilities - The total assets at the end of Q1 2024 were CNY 1,855,149,694.08, a decrease of 0.43% from the end of the previous year[6]. - Total assets as of March 31, 2024, were CNY 1,855,149,694.08, slightly down from CNY 1,863,168,849.07 at the end of 2023[14]. - Total liabilities decreased to CNY 809,680,853.37 from CNY 854,715,417.70 at the end of 2023[14]. - Inventory as of March 31, 2024, was CNY 325,347,663.33, down from CNY 332,232,706.24 at the end of 2023[12]. - Short-term borrowings increased to CNY 115,050,458.33 from CNY 95,489,165.29 at the end of 2023[13]. - Non-current assets totaled CNY 782,072,156.02 as of March 31, 2024, up from CNY 745,935,970.69 at the end of 2023[13]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,724, with the largest shareholder holding 44.95% of the shares[9]. - The company received government subsidies amounting to CNY 40,381,548.64, which are closely related to its normal business operations[7]. Comprehensive Income - The total comprehensive income for Q1 2024 was CNY 37,015,409.34, down from CNY 43,844,285.02 in Q1 2023[19]. - Other comprehensive income after tax for Q1 2024 was CNY 961,573.32, a decrease of 93.3% compared to CNY 14,231,350.22 in Q1 2023[19]. - The company received CNY 90,000,000.00 from the recovery of investments during Q1 2024[24].

证券代码：600833 证券简称：第一医药 公告编号：临 2024-030 上海第一医药股份有限公司 2024 年第一季度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海第一医药股份有限公司（以下简称"公司"）根据《上海证券交易所上市公司 自律监管指引第 3 号——行业信息披露（第四号——零售）》的相关要求，现将公司 2024 年第一季度主要经营数据披露如下： 一、报告期门店变动情况 截至 2024 年 3 月 31 日，公司拥有门店 174 家（含加盟店 18 家），总经营面积 19,366 平方米（不含加盟店面积）。2024 年 1-3 月，公司净增门店 3 家，其中，新开 门店 4 家，新增加盟店 3 家，关闭门店 4 家。截至期末，门店区域分布如下： 单位：家 | 区域 | 2023 年期末 | 2023 年期末 | 2024 | 年 1-3 | 月 | 2024 | 年 1-3 | 月 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | ...

上海第一医药股份有限公司 2023 年年度股东大会 会议资料 二○二四年四月二十九日 上海第一医药股份有限公司 2023 年年度股东大会会议资料 会议资料目录 | 一、2023 年年度股东大会会议议程………………………………… | 1 | | --- | --- | | 二、2023 年年度股东大会会议须知………………………………… | 2 | | 三、2023 年年度报告及摘要………………………………………… | 4 | | 四、2023 年度董事会工作报告……………………………………… | 5 | | 五、2023 年度监事会工作报告………………………………………10 | | | 六、2023 年度财务决算及 2024 年度财务预算报告 ………………14 | | | 七、2023 年度利润分配预案…………………………………………19 | | | 八、关于续聘财务报告审计会计师事务所的议案 …………………20 | | | 九、关于续聘内部控制审计会计师事务所的议案 …………………21 | | | 十、关于调整经营范围并修订《公司章程》相关条款的议案…… | 22 | | 十一、关于补选第十届董事会非独立董事 ...

重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 召开的日期时间：2024 年 4 月 29 日 13 点 30 分 召开地点：上海市徐汇区小木桥路 681 号 20 楼第三会议室 (五) 网络投票的系统、起止日期和投票时间。 证券代码：600833 证券简称：第一医药 公告编号：2024-025 上海第一医药股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 4 月 29 日 至 2024 年 4 月 29 日 股东大会召开日期：2024年4月29日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2024-026 上海第一医药股份有限公司 关于收到房屋征收补偿款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 一、本次交易概述 根据上海市黄浦区人民政府《上海市黄浦区人民政府房屋征收决定》（黄府征〔2021〕 9 号），上海第一医药股份有限公司（以下简称"公司"）位于上上海市黄浦区福州路 342-356 号的房屋被纳入征收范围。上述房屋由公司经营管理，曾主要用于对外出租经 营使用，部分为自用仓储。本次房屋征收单位为"上海市黄浦区住房保障和房屋管理局"， 房屋征收实施单位为"上海市黄浦第二房屋征收服务事务所有限公司"，房屋评估单位 为"上海房地产估价师事务所有限公司"，面积测量单位为"上海宝源建设工程勘测有 限公司"。 二、对公司的影响 本次被征收的房屋系由公司经营管理，曾主要用于对外出租经营使用，部分为自用 仓储。因此本次征收对公司业务不会产生重大影响。 公司将按照企业会计的相关规定，对上述征收补偿款进行会计处理，计入当期损益。 预计会对公司当年度经营 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2024-023 上海第一医药股份有限公司 上海第一医药股份有限公司董事会 2024 年 4 月 9 日 辞任后，吴平先生不再担任公司任何职务。截至本公告日，吴平先生未持有公司股 份，其工作已进行妥善交接，不会影响公司董事会正常运作，不会影响公司正常经营。 吴平先生在任职期间勤勉尽责、恪尽职守。公司董事会对吴平先生在任职期间对公 司所做的贡献表示衷心感谢！ 特此公告。 关于董事辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 上海第一医药股份有限公司（以下简称"公司"）董事会近日收到公司董事吴平先 生的书面辞任报告，吴平先生因已到法定退休年龄，申请辞去公司第十届董事会董事、 战略委员会委员、提名委员会委员等职务。根据《公司法》《公司章程》的有关规定， 吴平先生的辞任不会导致公司董事会低于法定最低人数，辞任报告自送达公司董事会之 日起生效。 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2024-024 上海第一医药股份有限公司 1 关于补选第十届董事会非独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 上海第一医药股份有限公司（以下简称"公司"）于 2024 年 4 月 8 日召开第十届董 事会第二十二次（临时）会议，审议通过了《关于补选第十届董事会非独立董事的议案》。 吴平先生因已到法定退休年龄，申请辞去公司第十届董事会董事、战略委员会委员、 提名委员会委员等职务。根据《公司章程》的规定，经公司股东提名及董事会提名委员 会资格审查通过，董事会同意提名张睿女士、陈陟峰先生（简历附后）为公司第十届董 事会非独立董事候选人，任期自股东大会审议通过之日起至第十届董事会届满为止，并 同意将本事项提交公司 2023 年年度股东大会审议。 特此公告。 上海第一医药股份有限公司董事会 2024 年 4 月 9 日 附非独立董事候选人简历： 1.张睿，女，47 岁，中国国籍，无境外永久居留权，研究生学历，中共党员。曾任 南京证券股份有限公司投资银行总 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,819,516,165.79, a decrease of 31.49% compared to CNY 2,655,908,524.74 in 2022[25] - The net profit attributable to shareholders for 2023 was CNY 89,275,234.00, down 37.81% from CNY 143,556,293.25 in the previous year[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 10,875,792.45, a significant decline of 92.23% compared to CNY 139,891,611.56 in 2022[25] - The net cash flow from operating activities was CNY 58,492,291.10, a decrease of 55.79% from CNY 132,310,966.22 in the previous year[25] - Basic earnings per share decreased by 37.50% to CNY 0.40 in 2023 compared to CNY 0.64 in 2022[26] - The weighted average return on equity dropped by 7.47 percentage points to 9.01% in 2023 from 16.48% in 2022[26] - The main business revenue was CNY 1,767,282,495.09, down 32.48% year-on-year, with a net profit attributable to shareholders of CNY 89,275,200, a decrease of 37.81%[46] - The company achieved operating revenue of CNY 1,819,516,165.79, a year-on-year decrease of 31.49%[46] Segment Performance - Net profit attributable to shareholders decreased significantly, primarily due to a 65.03% decline in the pharmaceutical wholesale segment, with a 15.75% decline after excluding related material sales[26] - Total operating revenue for 2023 was CNY 1,819,516,165.79, with a 15.84% increase in the retail segment but a 65.03% decrease in the wholesale segment[26] - The pharmaceutical retail business saw an operating revenue increase of 15.84% year-on-year, reaching CNY 1,220,391,256.49, while the pharmaceutical wholesale business decreased by 65.03% to CNY 546,891,238.60[46][50] Cash Flow and Investments - The net cash flow from operating activities decreased, primarily due to reduced operating profit[26] - Investment activities generated a net cash flow of CNY 167,140,961.81, a significant increase of 230.80% year-on-year[57] - Other income decreased by 87.99% to 454,413.56 RMB due to a reduction in government subsidies related to operations[60] - Investment income increased by 184.52% to 11,726,371.20 RMB, attributed to higher returns from financial instrument investments[60] - Fair value changes in financial instruments resulted in a gain of 12,137,397.26 RMB, a significant increase of 4143.85% compared to the previous year[60] Business Development and Strategy - The company expanded its retail network to 173 stores, achieving full coverage in all 16 districts of Shanghai[33] - The company launched a new health town concept, integrating various health services and products, enhancing customer experience[33] - The company initiated a franchise business model, adding 7 new franchise stores during the year[33] - The company plans to enhance its main store types and optimize product planning based on consumer demand[33] - The company actively engaged in community health services and marketing activities, enhancing brand influence and customer interaction[34] - The company focused on digital transformation to improve management efficiency and customer engagement[35] - The company is positioned as a well-established player in the Shanghai pharmaceutical distribution sector, with a comprehensive range of services and products[40] Risk Management and Governance - The company has outlined potential risks in its future development plans, which investors should be aware of[10] - The company will implement measures to strengthen internal controls and risk management to protect shareholder interests[106] - The company has maintained a strong governance structure to protect shareholder rights, focusing on the interests of minority shareholders[172] - The company has established an independent financial accounting department to ensure financial independence and compliance with tax regulations[121] Human Resources and Talent Development - The company has focused on talent development, particularly for pharmacists, to improve service quality and operational efficiency[44] - The company has implemented a flexible compensation policy based on performance, aiming to attract and retain talent[147] - In 2023, the company focused on building a talent development system, emphasizing the cultivation of different levels of talent[148] - The training plan includes various methods such as internal training, external training, and online courses to enhance employee skills[148] Community Engagement and Social Responsibility - The company conducted over 30 online and 30 offline patient education sessions in 2023, reaching more than 6,000 participants[174] - The company organized approximately 400 community service activities in 2023, serving over 40,000 individuals[174] - The company has committed 256,300 yuan to poverty alleviation projects from 2021 to 2023, specifically for the "Gray Road Mango Greenhouse Project"[176] Shareholder and Board Activities - The company held 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, particularly minority shareholders[110] - The board of directors consists of 9 members, including 3 independent directors, and operates under various committees to ensure compliance with legal requirements[112] - The company has established a performance evaluation system linking executive compensation to business performance, ensuring transparency in the hiring of senior management[114] Environmental and Compliance Issues - The company did not invest any funds in environmental protection during the reporting period, with an investment amount of 0 million yuan[168] - The company has not been subject to any administrative penalties related to environmental issues during the reporting period[169] - The company has not experienced any insider trading incidents during the reporting period, maintaining compliance with insider information management regulations[119]